Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib –final appraisal consultation document

Source:
National Institute for Health and Care Excellence - NICE
Publisher:
National Institute for Health and Care Excellence
Publication date:
15 February 2019

Abstract

This DRAFT guidance recommends brigatinib for treating anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.